Aberrantly glycosylated IgA1 in IgA nephropathy: What we know and what we don’t know

Yukako Ohyama, Matthew B. Renfrow, Jan Novak, Kazuo Takahashi

研究成果: ジャーナルへの寄稿総説査読

28 被引用数 (Scopus)


IgA nephropathy (IgAN), the most common primary glomerular disease worldwide, is characterized by glomerular deposition of IgA1-containing immune complexes. The IgA1 hinge region (HR) has up to six clustered O-glycans consisting of Ser/Thr-linked N-acetylgalactosamine usually with β1,3-linked galactose and variable sialylation. Circulating levels of IgA1 with abnormally O-glycosylated HR, termed galactose-deficient IgA1 (Gd-IgA1), are increased in patients with IgAN. Current evidence suggests that IgAN is induced by multiple sequential pathogenic steps, and production of aberrantly glycosylated IgA1 is considered the initial step. Thus, the mechanisms of biosynthesis of aberrantly glycosylated IgA1 and the involvement of aberrant glycoforms of IgA1 in disease development have been studied. Furthermore, Gd-IgA1 represents an attractive biomarker for IgAN, and its clinical significance is still being evaluated. To elucidate the pathogenesis of IgAN, it is important to deconvolute the biosynthetic origins of Gd-IgA1 and characterize the pathogenic IgA1 HR O-glycoform(s), including the glycan structures and their sites of attachment. These efforts will likely lead to development of new biomarkers. Here, we review the IgA1 HR O-glycosylation in general and the role of aberrantly glycosylated IgA1 in the pathogenesis of IgAN in particular.

ジャーナルJournal of Clinical Medicine
出版ステータス出版済み - 02-08-2021

All Science Journal Classification (ASJC) codes

  • 医学一般


「Aberrantly glycosylated IgA1 in IgA nephropathy: What we know and what we don’t know」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。